Tropical Medicine
DTM&H
Diplomas

The DTM&H

A clear, exam-focused route through the Diploma in Tropical Medicine & Hygiene (DTM&H) — examined by the Worshipful Society of Apothecaries. Here is what the exam involves, and the question bank, image bank and revision guide we have built to revise for it. It includes an image trainer for the specimen-image paper: 100 real CDC DPDx specimens to identify.

This is one of our Diplomas — tropical and travel-medicine qualifications taken by doctors heading overseas, or working with returning travellers and migrant health. The DTM&H is assessed by four online papers: two best-of-five MCQ papers, a preventative-medicine short-structured-question paper, and a parasitology & entomology specimen-image paper.

What the exam involves

Best-of-five papers, plus a specimen image paper

The DTM&H tests clinical decisions and bedside-to-bench recognition at candidate level — not specialist trivia. Our resources are built squarely around those papers.

4 papers
Two best-of-five MCQ papers, a preventative-medicine short-answer paper, and a parasitology & entomology image paper.
Image SAQ
A parasite, ova and vector recognition paper — name the specimen, give the diagnosis.
Apothecaries
Examined by the Worshipful Society of Apothecaries (SocApoth), London.
WHO-first
Grounded in WHO and international guidance, with UK practice noted where it differs.
Everything in one place

The complete DTM&H toolkit

One membership unlocks the question bank, the image bank and the revision guide — built to be used together.

850 questions

The Question Bank

Best-of-five MCQs across all twelve modules, each with a teaching explanation, drill-by-module and timed mock papers.

Get access →

100 specimens

The Image Bank

Real CDC public-domain specimens for the SAQ paper — blood films, ova, protozoa and vectors, in Learn, timed-mock and by-group modes.

Get access →

12 chapters

The Revision Guide

A high-yield, interactive online textbook, one chapter for each question-bank module, from malaria to nutrition and tropical paediatrics. Tropical non-communicable disease is taught in Core Lens and Core Curriculum.

Get access →

The syllabus

Twelve modules, fully mapped

Covered across the question bank, image bank and guide, mapped to the official blueprint.

1Malaria
2Tuberculosis & leprosy
3HIV & OIs
4Enteric & diarrhoeal
5Arboviruses & VHF
6Helminths
7Protozoa
8Zoonoses & bacterial
9Travellers’ health
10Diagnostic parasitology
11Public health & control
12Nutrition & paediatrics

Get the whole DTM&H suite

One membership · 12 months’ full access
£49.99
  • 850 best-of-five questions with teaching explanations
  • 100-specimen image bank for the SAQ paper
  • All twelve interactive revision-guide chapters
  • Core 10, Core Compass, Core Calendar, Core Lens, Core Tools and the SSQ Trainer
  • One-time payment — no subscription
Get access →

For revision only. Core Revision is an independent revision resource and is not affiliated with, endorsed by, or connected to the Worshipful Society of Apothecaries or any examining body. Content summarises international (WHO-first) guidance current at the time of writing and is not a substitute for current local protocols or clinical judgement.

Try before you buy

Try ten DTM&H questions, free

Revision aid, not clinical advice. This page is educational material written for exam preparation. It is not a substitute for the current guideline or for clinical judgement, and must not be relied on for the care of any individual. Always check up-to-date national guidance and verify independently before acting on anything here.

One question from each of ten DTM&H modules, with the same explanation members see after every answer: the Core Lens, a Deep Dive and a Founder’s Tip. No sign-up, no timer, nothing saved.

DTM&H · Arboviruses & Viral Haemorrhagic FeversQuestion 1 of 10 · single best answer

Zika virus: advice in pregnancy

Scenario: A 29-year-old woman who is 14 weeks pregnant attends your travel clinic. She and her partner are hoping to take a holiday to a region where there is current, active Zika virus transmission. She is otherwise well, the pregnancy is uncomplicated, and she has no symptoms. She asks specifically what she should do about the trip and how to keep the baby safe.

Question: What is the most appropriate advice?

Pick an answer to reveal the explanation.

CorrectIncorrect

The correct answer is C. Advise postponing non-essential travel to active-transmission areas until after pregnancy; if she still travels, advise scrupulous mosquito-bite avoidance day and night and consistent condom use to prevent sexual transmission, because of the risk of congenital Zika syndrome.

Core Lens: High-Yield Takeaways

  • Pregnancy plus active Zika transmission means postpone non-essential travel. — UKHSA/NaTHNaC advice is that pregnant women should defer non-essential travel to areas with active (outbreak) Zika transmission until after the pregnancy.
  • Bite avoidance is round-the-clock. — The Aedes mosquito vector bites predominantly in daylight, so repellent, covering clothing and treated nets are advised by day and night, indoors and out, if travel goes ahead.
  • Zika is sexually transmitted, so condoms matter. — Consistent and correct condom (barrier) use reduces sexual transmission during and for a defined period after travel, protecting the pregnancy.
  • The stake is congenital Zika syndrome. — Maternal infection can cause microcephaly and other serious fetal brain abnormalities, which is why precautions are framed around protecting the fetus.
Click here for Deep Dive

Why Zika Is a Pregnancy Problem First

For most people Zika virus infection is mild or silent — a brief illness with low-grade fever, rash, conjunctivitis and arthralgia, if there are symptoms at all. The reason it dominates travel advice is its effect in pregnancy: vertical transmission can cause congenital Zika syndrome, a constellation that includes microcephaly, intracranial calcification and other brain abnormalities, with lifelong consequences. Because the virus is transmitted both by daytime-biting Aedes mosquitoes and sexually, prevention has two limbs — bite avoidance and barrier contraception — and the safest single measure for a pregnant traveller is simply not to go to an active-transmission area until after delivery.

Why This Is the Right Move

UKHSA and NaTHNaC (TravelHealthPro) advise that pregnant women postpone non-essential travel to areas with active Zika transmission until after pregnancy. Where travel is unavoidable, the woman and her partner should understand the risk and follow scrupulous mosquito-bite avoidance both indoors and outdoors, day and night, given the daytime-biting habit of the vector. Because Zika can be transmitted sexually, consistent condom or barrier use is advised during travel and for a specified period afterwards, even if neither partner has symptoms. On return, a pregnant woman who has travelled to a risk area should speak to her GP or midwife for assessment and fetal monitoring, whether or not she has been unwell. Because the precise list of risk areas and the recommended durations of precaution are revised as the epidemiology and country classifications change, current UKHSA/NaTHNaC sources should be checked at the time of advising.

Why the Other Options Don’t Fit

  • Option A: Reassuring her that there is no risk is simply incorrect — congenital Zika syndrome is exactly the risk the advice exists to prevent.
  • Option B: There is no licensed Zika vaccine and no antiviral chemoprophylaxis; offering them is unsafe and false reassurance.
  • Option D: Doxycycline addresses malaria, not Zika, and is generally avoided in pregnancy; it does nothing to prevent congenital Zika syndrome.
  • Option E: Zika is well documented to be sexually transmissible, so advising that condoms are unnecessary removes a key protective measure.

“Red Flags” and Key Decision Points

  • Active-transmission (outbreak) area versus low-level risk: the advice to postpone is strongest for areas with current active transmission — always check the current country classification.
  • Symptoms after travel in pregnancy: rash, fever, conjunctivitis or arthralgia warrant prompt assessment and discussion with obstetrics and the local laboratory about testing.
  • A male partner who has travelled: sexual transmission means his exposure matters too — barrier precautions apply to the couple, not just the pregnant woman.
  • Planning a pregnancy soon after travel: conception is advised to be deferred for a recommended interval after exposure — check the current guidance.

Relevance to Clinical Practice

Pre-travel counselling is a high-value, low-cost intervention, and Zika in pregnancy is one of its clearest wins: a few minutes of advice can prevent a devastating congenital outcome. In travel and global-health practice the same framework — assess the destination’s current risk, advise deferral where the stakes are high, and otherwise stack bite-avoidance and barrier precautions — applies across vector-borne disease. Because risk maps and recommended precaution periods are updated as outbreaks evolve, the professional habit is to consult the live UKHSA/NaTHNaC country information rather than rely on memory.

Founder’s Tip

For a pregnant traveller and an active Zika area the best advice is usually “don’t go yet”; if she must, it is bites by day and night and condoms throughout — the threat is the baby’s brain, not the mother’s fever.

Core Summary: Pregnant women should postpone non-essential travel to active Zika-transmission areas until after pregnancy; if they travel, scrupulous round-the-clock mosquito-bite avoidance and consistent condom use are advised to prevent sexual transmission and congenital Zika syndrome, per current UKHSA/NaTHNaC guidance.

DTM&H · Enteric & Diarrhoeal InfectionsQuestion 2 of 10 · single best answer

Enteric: hepatitis A prevention for travellers

Scenario: A healthy 24-year-old plans a three-month backpacking trip through rural South and South-East Asia, including areas with poor sanitation, in eight weeks time. She attends a travel clinic for advice. She has no significant medical history, takes no regular medication and has had no previous travel vaccinations. She asks specifically how to protect herself against hepatitis A.

Question: Which is the most appropriate advice regarding hepatitis A?

Pick an answer to reveal the explanation.

CorrectIncorrect

The correct answer is C. She should receive hepatitis A vaccination before travel, alongside food and water hygiene advice.

Core Lens: High-Yield Takeaways

  • Vaccinate the at-risk traveller. — Hepatitis A vaccine is recommended for travellers to endemic areas with poorer sanitation; it is safe, effective and gives long-lasting protection after a primary course and booster.
  • It is a faeco-oral infection. — Hepatitis A spreads through contaminated food and water, so the vaccine complements (does not replace) advice on safe food, water and personal hygiene.
  • It is usually self-limiting and never chronic. — Hepatitis A causes an acute, self-limited illness and does not lead to chronic infection or cirrhosis, although it can be more severe in older adults.
  • There is time to vaccinate. — With eight weeks before travel there is ample time for vaccination; a single dose protects for the trip, with a later booster for long-term immunity.
Click here for Deep Dive

A Vaccine-Preventable Traveller’s Hepatitis

Hepatitis A virus (HAV) is transmitted by the faeco-oral route, chiefly through food and water contaminated with the virus, and is common in regions with limited sanitation. For non-immune travellers from low-prevalence countries visiting endemic areas, it is one of the most frequent vaccine-preventable infections. The illness is an acute hepatitis with malaise, anorexia, nausea and jaundice; it is self-limiting and does not become chronic, but it can cause significant morbidity and, rarely, fulminant disease, with risk rising in older adults and those with chronic liver disease.

Why This Is the Right Move

WHO and NaTHNaC (TravelHealthPro) recommend hepatitis A vaccination for travellers to areas of moderate or high endemicity, particularly where sanitation is poor, given as part of pre-travel risk assessment alongside food, water and hygiene precautions. Inactivated hepatitis A vaccines are highly immunogenic: a single dose induces protective antibody in nearly all healthy adults within a few weeks and is effective for the journey, while a second (booster) dose 6 to 12 months later confers long-term, probably lifelong, protection. Where protection against both hepatitis A and B is wanted, a combined vaccine is available and can be given on a standard or accelerated schedule. The vaccine is the mainstay of prevention; human normal immunoglobulin is now reserved for specific situations (for example certain at-risk contacts or those who cannot be vaccinated). With eight weeks’ lead time, this traveller can be fully prepared, and even travellers presenting close to departure should still be vaccinated because protection develops quickly.

Why the Other Options Don’t Fit

  • Option A: Hepatitis A is faeco-orally (food- and water-) transmitted, not bloodborne, so specific measures (vaccination plus hygiene advice) are clearly indicated.
  • Option B: There is no role for daily antiviral prophylaxis against hepatitis A; prevention is by vaccination and hygiene, not antivirals.
  • Option D: Vaccination, not immunoglobulin, is the principal means of protecting travellers; immunoglobulin has a limited, specific role.
  • Option E: Hepatitis A does not become chronic; this is incorrect and would wrongly deny her effective vaccination.

“Red Flags” and Key Decision Points

  • Last-minute traveller: the vaccine still works given even shortly before departure, so do not withhold it for short lead times; immunoglobulin may be added for selected high-risk, imminent travellers.
  • Older age or chronic liver disease: higher risk of severe hepatitis A — ensure vaccination and counselling.
  • Possible existing immunity: those who grew up in endemic areas or had prior infection may already be immune; serology can avoid unnecessary vaccination where relevant.
  • Signs of acute liver failure (rare): deepening jaundice, confusion or bleeding warrant urgent assessment.

Relevance to Clinical Practice

Pre-travel advice is a core opportunity to prevent hepatitis A. The practical approach is structured risk assessment based on destination, duration, activities and the traveller’s health, offering hepatitis A vaccine to those visiting endemic regions and reinforcing food and water hygiene (“boil it, cook it, peel it, or forget it”). In endemic countries themselves, hepatitis A is largely a childhood infection conferring lifelong immunity, and improving sanitation and safe water remain the population-level controls; vaccination strategy is tailored to local epidemiology.

Founder’s Tip

Hepatitis A is the classic vaccine-preventable traveller’s infection: one pre-travel dose covers the trip, a booster at 6 to 12 months locks in long-term immunity, and hygiene advice fills the gap.

Core Summary: Hepatitis A is a faeco-oral, self-limiting (never chronic) hepatitis; for travellers to endemic, poorly sanitated areas, WHO and NaTHNaC recommend hepatitis A vaccination before travel together with food and water hygiene advice, with a booster for long-term protection.

DTM&H · Helminth InfectionsQuestion 3 of 10 · single best answer

Schistosomiasis: treatment

Scenario: A 26-year-old traveller presents six weeks after a gap-year trip during which he swam and waded in fresh water in Lake Malawi. He describes painless blood at the end of his urine stream on several occasions. He is systemically well. Urine microscopy shows red cells and characteristic parasite eggs with a prominent terminal spine, consistent with Schistosoma haematobium.

Question: According to WHO guidance, what is the treatment of choice?

Pick an answer to reveal the explanation.

CorrectIncorrect

The correct answer is A. Praziquantel.

Core Lens: High-Yield Takeaways

  • Praziquantel is the drug for all human schistosomiasis. — WHO recommends praziquantel as the treatment of choice for Schistosoma haematobium, mansoni and the other species, given orally at 40 mg/kg (commonly as a single day’s treatment, sometimes split into two doses).
  • Terminal-spined eggs in urine equals S. haematobium. — Painless terminal haematuria weeks after freshwater contact in sub-Saharan Africa, with terminal-spine eggs, is the classic picture of urinary schistosomiasis.
  • Timing affects egg yield. — Praziquantel works on adult worms, so very early (pre-patent) infection may need a repeat course after several weeks once eggs are being produced; a single negative early test does not exclude infection.
  • Freshwater exposure is the exposure to ask about. — Swimming, wading or rafting in lakes and rivers in endemic Africa (Lake Malawi is notorious) is the key history that should prompt screening even in the asymptomatic.
Click here for Deep Dive

One Drug, A Global Disease

Schistosomiasis is one of the most prevalent parasitic diseases worldwide and a WHO-prioritised neglected tropical disease. Infection follows skin contact with fresh water containing cercariae released by intermediate-host snails; the adult flukes then live in the venous plexuses — around the bladder for S. haematobium, the mesentery for S. mansoni. Eggs, not the worms themselves, drive much of the pathology through granulomatous inflammation: chronic urinary schistosomiasis causes haematuria, bladder fibrosis, obstructive uropathy and, in the long term, an increased risk of squamous-cell bladder cancer, while intestinal and hepatic disease causes periportal fibrosis and portal hypertension. Against this whole spectrum, praziquantel is the mainstay of both individual treatment and population-level mass drug administration.

Why This Is the Right Move

The history (freshwater contact in Lake Malawi), the symptom (terminal haematuria) and the laboratory finding (eggs with a terminal spine) together identify S. haematobium, for which WHO recommends praziquantel 40 mg/kg orally. It is well tolerated, inexpensive and the same drug used across the schistosome species, which is why it underpins WHO control programmes. Because praziquantel is most active against mature worms, a traveller treated in early infection may be re-tested and re-treated a few weeks later to catch worms that were immature at first dosing; checking for and treating co-infections and following up with urine examination completes the management.

Why the Other Options Don’t Fit

  • Option B: Albendazole is a broad anthelmintic for soil-transmitted helminths and tissue nematodes (and part of neurocysticercosis therapy), but it is not the treatment for schistosomiasis.
  • Option C: Ivermectin treats strongyloidiasis, onchocerciasis and scabies; it has no useful activity against schistosomes.
  • Option D: Diethylcarbamazine is used in lymphatic filariasis and loiasis, not schistosomiasis.
  • Option E: Metronidazole targets anaerobes and protozoa such as amoebae and Giardia, not trematodes.

“Red Flags” and Key Decision Points

  • Acute schistosomiasis (Katayama syndrome): fever, urticaria and eosinophilia weeks after exposure can be immune-mediated — corticosteroid cover may be needed and praziquantel timing reconsidered, as the early worms may not yet be susceptible.
  • Neurological symptoms: back pain, leg weakness or bladder dysfunction can signal spinal cord schistosomiasis — a neurological emergency requiring urgent specialist input and steroids.
  • Visible haematuria that persists after treatment: arrange urological assessment to exclude structural disease and, in older patients from endemic areas, bladder malignancy.
  • Asymptomatic exposed travellers: screen with serology and urine/stool examination even without symptoms, because untreated infection causes cumulative organ damage.

Relevance to Clinical Practice

Praziquantel’s affordability and single-course simplicity are precisely what make schistosomiasis control feasible in resource-limited settings, where preventive chemotherapy through mass drug administration to at-risk communities (notably school-age children) is a cornerstone WHO strategy alongside water, sanitation and snail control. For the individual returning traveller, the practical lesson is to take a freshwater-exposure history, recognise terminal haematuria, confirm with urine microscopy or serology, treat with praziquantel and arrange follow-up testing, remembering that early treatment may need repeating.

Founder’s Tip

Fresh water in Africa plus blood at the end of the stream equals S. haematobium until proven otherwise — and praziquantel is the answer for every schistosome species.

Core Summary: Urinary schistosomiasis (S. haematobium), suggested by terminal haematuria and terminal-spined eggs after African freshwater contact, is treated with praziquantel 40 mg/kg per WHO guidance, with repeat testing and treatment if given very early.

DTM&H · MalariaQuestion 4 of 10 · single best answer

Malaria: transfusion-transmitted malaria without travel history

Scenario: A 54-year-old man who has never left the United Kingdom is admitted with a one-week history of swinging fevers, rigors, headache and jaundice. He is thrombocytopenic and mildly anaemic. He has had no recent surgery, but received a red-cell transfusion six weeks ago during a hospital admission. His blood film is reported as showing intra-erythrocytic ring forms. The admitting team is puzzled because he has no travel history.

Question: Which conclusion about this presentation is correct?

Pick an answer to reveal the explanation.

CorrectIncorrect

The correct answer is C. Transfusion-transmitted malaria should be diagnosed and treated, and the donation investigated.

Core Lens: High-Yield Takeaways

  • Malaria is not excluded by the absence of travel. — In non-endemic countries malaria without a travel history occurs through blood transfusion or organ transplant (induced malaria), from mother to child (congenital), nosocomially, or via an infected mosquito carried on an aircraft (airport malaria).
  • Intra-erythrocytic ring forms with fever, rigors, jaundice and thrombocytopenia are malaria until proven otherwise. — The film should be taken at face value and acted on, not dismissed as an artefact.
  • The transfusion six weeks earlier is the likely route. — Transfusion-transmitted malaria delivers blood-stage parasites directly, so there is no liver phase and therefore no hypnozoite, whatever the species; the incubation reflects the inoculum and can be within weeks.
  • This is a transfusion incident as well as a clinical emergency. — The implicated donation and donor must be traced and investigated, and the case reported through haemovigilance, because other recipients may be at risk.
Click here for Deep Dive

Malaria With No Passport Stamp

Clinicians in non-endemic settings are trained to anchor the diagnosis of malaria on travel, which means non-imported cases are repeatedly missed or delayed — sometimes fatally. The recognised mechanisms of malaria acquired without travel are induced malaria (transfusion of infected blood, transfusion of cellular components, organ transplantation, or shared needles), congenital malaria (transplacental or peripartum transmission from an infected mother), nosocomial transmission, and the rare phenomenon of airport, port or baggage malaria, in which an infected anopheline mosquito is carried from an endemic country and bites a person near the point of arrival. Each shares the same trap: the clinician does not think of malaria because the travel question is negative.

Why This Is the Right Move

In transfusion-transmitted malaria, viable parasitised red cells are infused directly into the recipient, bypassing the mosquito and liver stages. Any human malaria species can be transmitted this way, and because there is no pre-erythrocytic phase the incubation period relates to the parasite load transfused rather than the usual mosquito-bite incubation. This man has the classic syndrome (fever, rigors, jaundice, thrombocytopenia, anaemia) with ring forms on film and a recent transfusion: the correct action is to confirm the species and parasitaemia, treat the malaria appropriately and promptly (severe falciparum would mandate parenteral artesunate), and simultaneously trigger the transfusion-incident pathway — quarantine related components, trace and test the donor, look back at other recipients of that donor, and report through haemovigilance. Standard texts (Manson’s Tropical Diseases) and UK guidance emphasise considering malaria regardless of travel history in any compatible febrile illness.

Why the Other Options Don’t Fit

  • Option A: The whole point of induced, congenital and airport malaria is that travel may be absent; excluding malaria on a negative travel history is the error that kills these patients.
  • Option B: Dismissing genuine ring forms as artefact in a septic, jaundiced, thrombocytopenic patient is dangerous; the film should prompt urgent species identification and treatment, with senior haematology review if there is any doubt.
  • Option D: Immunosuppression is not a prerequisite for malaria; a fully immunocompetent person who receives parasitised blood will develop infection.
  • Option E: All human Plasmodium species can be transmitted by transfusion, and falciparum in particular can be rapidly life-threatening, so treatment is urgent and species identification matters.

“Red Flags” and Key Decision Points

  • Fever plus recent transfusion, transplant or shared needles: include malaria, regardless of travel, and request urgent films or a rapid diagnostic test.
  • Neonatal fever in an infant of a mother from an endemic area: consider congenital malaria even if the baby was born in a non-endemic country.
  • Unexplained febrile illness near a major international airport: airport or baggage malaria is rare but real and should enter the differential when no other route is found.
  • Features of severe malaria (impaired consciousness, jaundice, renal impairment, high parasitaemia): escalate to parenteral artesunate and critical-care support without waiting to resolve the epidemiology.

Relevance to Clinical Practice

In endemic and resource-limited settings, transfusion-transmitted malaria is a recognised hazard of an essential, life-saving intervention, and is mitigated by donor selection, deferral of recently exposed donors, and where feasible parasite screening of donations — balanced against the risk of depleting an already scarce blood supply. The transferable clinical lesson for any setting is to keep malaria in the differential of an unexplained febrile illness even when travel is denied, to act on a positive film immediately, and to recognise that a single transfusion-transmitted case is also a public-health and haemovigilance event affecting the donor and other recipients.

Founder’s Tip

“No travel” never excludes malaria: ask about transfusion, transplant, pregnancy and proximity to airports, and treat ring forms on the film as real until a senior reviewer says otherwise.

Core Summary: Malaria can be acquired without travel through transfusion or transplantation (induced), from mother to child (congenital), nosocomially, or via an airport-borne mosquito; ring forms with a compatible febrile illness after a recent transfusion indicate transfusion-transmitted malaria, which must be treated urgently and investigated as a transfusion incident.

DTM&H · Nutrition, Maternal & Child Health & Tropical NCDsQuestion 5 of 10 · single best answer

IMCI: recognising the sick child

Scenario: At a rural health centre you assess an 18-month-old child using the WHO Integrated Management of Childhood Illness (IMCI) approach. The mother reports the child has been off feeds; when she offers the breast and a cup of water, the child is too weak to drink or breastfeed at all. The child is irritable but has no convulsions and is not unconscious. You are deciding what the IMCI chart directs you to do.

Question: According to the WHO IMCI approach, which action is most appropriate?

Pick an answer to reveal the explanation.

CorrectIncorrect

The correct answer is E. Recognise inability to drink or breastfeed as a general danger sign, give appropriate pre-referral treatment and refer the child urgently to hospital.

Core Lens: High-Yield Takeaways

  • Inability to drink or breastfeed is a general danger sign. — In IMCI, the general danger signs are: unable to drink or breastfeed, vomits everything, convulsions, and lethargy or unconsciousness; any one marks a child as seriously ill.
  • A general danger sign mandates urgent referral. — The child needs complete assessment, immediate pre-referral treatment, and urgent referral to hospital — not outpatient management.
  • Pre-referral treatment comes before transport. — Give the appropriate first dose (for example pre-referral antibiotics, and other urgent treatments as indicated by the classification) before the child leaves, to cover the journey.
  • IMCI is triage by syndrome, not by laboratory. — The approach is built to work without investigations, so action is never delayed waiting for tests in a first-level facility.
Click here for Deep Dive

How IMCI Structures the Sick-Child Encounter

IMCI (“assess, classify, identify treatment”) is designed for first-level health workers managing children aged two months up to five years where diagnostics are limited. The very first step in assessing any sick child is to check for general danger signs, because their presence overrides everything else and identifies a child who is likely to be seriously ill. The four general danger signs are: unable to drink or breastfeed, vomits everything, convulsions, and lethargic or unconscious. Only after checking these does the worker move through the main symptom assessments (cough or difficult breathing, diarrhoea, fever, ear problem) and nutritional and immunisation status. A child with any general danger sign is classified in the severe (pink) category, given urgent pre-referral treatment, and referred.

Why This Is the Right Move

This child cannot drink or breastfeed at all — a textbook general danger sign. IMCI therefore directs the worker to complete the rapid assessment, give appropriate urgent pre-referral treatment, and refer urgently to hospital. The pre-referral treatment depends on the full classification but typically includes the first dose of an appropriate antibiotic and treatment of any other identified severe classification, plus measures to prevent low blood sugar (a breastfeed or sugar water if the child can take it, or referral guidance if not) and keeping the child warm. Recognising the danger sign and acting on it — rather than managing the child as a routine outpatient — is the single most important decision in the encounter and is what IMCI is built to ensure.

Why the Other Options Don’t Fit

  • Option A: Classifying this as a simple cough and discharging on oral amoxicillin ignores a general danger sign; a child unable to drink cannot be managed as a mild outpatient illness and needs referral, not a home prescription.
  • Option B: Reassurance and home feeding miss a severe classification entirely; “return if convulsions develop” dangerously waits for deterioration when the child already meets criteria for urgent referral.
  • Option C: IMCI is explicitly designed to act without laboratory results at first-level facilities; withholding treatment for a blood count and film delays life-saving pre-referral care.
  • Option D: Oral rehydration solution alone with a one-week review treats a child who cannot even drink as if she had mild dehydration; this under-treats a danger-sign presentation and omits urgent referral.

“Red Flags” and Key Decision Points

  • Any single general danger sign: unable to drink or breastfeed, vomiting everything, convulsions, or lethargy/unconsciousness each independently triggers urgent referral — you do not need all four.
  • Pre-referral dose before departure: never send a severely ill child without the first dose of treatment; the journey to hospital can be long and the dose buys time.
  • Fast breathing as a separate decision: in IMCI, age-specific fast breathing without danger signs classifies as pneumonia for oral amoxicillin at home — but that pathway does not apply once a general danger sign is present, which always escalates care.
  • Prevent hypoglycaemia and keep warm: simple supportive measures during referral (a feed if able, warmth) matter as much as the antibiotic in a collapsing small child.

Relevance to Clinical Practice

IMCI underpins frontline child health across much of the tropical world and is exactly the framework a clinician supervising or training first-level workers must know cold. Its power is that it converts limited resources and limited diagnostics into safe, reproducible triage: check danger signs first, classify by colour-coded severity, treat and refer accordingly. For the doctor, the high-yield skill is recognising the general danger signs instantly and ensuring pre-referral treatment is given before transfer — because in settings where the nearest hospital is hours away, that first dose and the decision to refer are frequently the difference between survival and death.

Founder’s Tip

“Can’t drink, vomits everything, fitting, or floppy — refer.” Any one IMCI general danger sign means urgent referral after a pre-referral dose; never manage such a child at home.

Core Summary: Inability to drink or breastfeed is an IMCI general danger sign, so the correct action is complete the assessment, give appropriate pre-referral treatment and refer the child urgently to hospital — not home antibiotics, reassurance, awaiting tests, or oral rehydration alone.

DTM&H · Parasitology & EntomologyQuestion 6 of 10 · single best answer

Malaria vector biology

Scenario: You are advising a district health team in rural East Africa on a malaria control programme. They plan to scale up long-lasting insecticidal nets and indoor residual spraying and ask you to explain, in simple terms, exactly which insect transmits human malaria and why these two interventions are expected to work against it.

Question: Which insect is responsible for transmitting human malaria?

Pick an answer to reveal the explanation.

CorrectIncorrect

The correct answer is D. Human malaria is transmitted by the female Anopheles mosquito, which bites mainly at night.

Core Lens: High-Yield Takeaways

  • Only the female Anopheles transmits human malaria. — She needs a blood meal to develop her eggs; in doing so she takes up and later injects Plasmodium sporozoites, completing the parasite’s life cycle.
  • Anopheles bites predominantly at night. — Peak biting is dusk to dawn, which is precisely why interventions that protect people while they sleep are so effective.
  • Night biting underpins LLINs and IRS. — Long-lasting insecticidal nets protect the sleeping person and kill mosquitoes that land on them, while indoor residual spraying kills mosquitoes that rest on walls after feeding indoors.
  • Vector identification drives control strategy. — Knowing the vector’s species, biting time and resting behaviour determines whether nets, spraying, larval source management or a combination will work in a given setting.
Click here for Deep Dive

Know Your Vector, Win Your Programme

Malaria is caused by Plasmodium parasites but is delivered by a single genus of mosquito: Anopheles. The distinction matters enormously for control, because the whole architecture of modern malaria prevention is built around the specific biology of this vector. Only female mosquitoes bite, because only they require the protein in a blood meal to mature their eggs; the male feeds on plant nectar and plays no part in transmission. When a female Anopheles bites an infected person she ingests gametocytes, the parasite develops within her over days, and sporozoites accumulate in her salivary glands ready to infect the next person she bites.

Why This Is the Right Move

WHO’s two core vector-control interventions — long-lasting insecticidal nets and indoor residual spraying — are effective precisely because Anopheles species characteristically bite late at night and often rest indoors. A net protects the sleeping occupant during the high-risk hours and, being insecticide-treated, kills or repels mosquitoes that contact it; residual spraying leaves insecticide on interior walls so that mosquitoes resting after an indoor blood meal pick up a lethal dose. Both interventions exploit the night-biting, indoor-resting habit of the vector. Where mosquitoes adapt to bite earlier, outdoors, or rest outdoors, these tools lose traction — which is exactly why surveillance of vector behaviour is part of every serious programme.

Why the Other Options Don’t Fit

  • Option A: Aedes mosquitoes are day-biting vectors of arboviruses such as dengue and Zika, not malaria; their daytime habit is also why nets and indoor spraying alone are a poor fit for Aedes control.
  • Option B: The male Anopheles feeds on nectar and never takes a blood meal, so it cannot transmit malaria.
  • Option C: Culex mosquitoes transmit lymphatic filariasis and arboviruses such as West Nile and Japanese encephalitis, not human malaria.
  • Option E: The Phlebotomus sandfly transmits leishmaniasis and sandfly fever, not malaria.

“Red Flags” and Key Decision Points

  • Outdoor and early-evening biting: behavioural resistance that undermines nets and indoor spraying and calls for complementary measures such as repellents and larval source management.
  • Insecticide resistance: rising pyrethroid resistance threatens both LLINs and IRS, so resistance monitoring and rotation of insecticide classes are essential.
  • Larval habitat near dwellings: Anopheles favour clean, often sunlit standing water, so identifying and managing breeding sites complements adult control.
  • Population net use and coverage: nets only work if hung, intact and slept under every night — uptake and condition are as important as distribution.

Relevance to Clinical Practice

For the travelling or resource-limited-setting clinician, the vector’s night-biting behaviour is also the basis of personal protection advice: cover up after dusk, use a repellent containing DEET, and sleep under an insecticide-treated net. At population level, understanding that the female Anopheles bites at night and rests indoors is what justifies investing scarce resources in nets and residual spraying rather than untargeted measures. Communicating this clearly to a district team helps them choose, deploy and sustain the interventions most likely to cut transmission.

Founder’s Tip

“Anopheles at night, Aedes by day” — the female Anopheles’ after-dark biting is the single fact that explains why bed nets and indoor spraying are the backbone of malaria control.

Core Summary: Human malaria is transmitted by the night-biting female Anopheles mosquito, and it is this nocturnal, indoor-resting behaviour that makes long-lasting insecticidal nets and indoor residual spraying the core WHO vector-control interventions.

DTM&H · Protozoal InfectionsQuestion 7 of 10 · single best answer

Chagas disease: antitrypanosomal treatment

Scenario: A 9-year-old child, recently arrived from a rural area of Bolivia, is found to have Trypanosoma cruzi infection on serology and confirmatory testing after a sibling was diagnosed. The child is asymptomatic, with a normal cardiovascular examination and a normal electrocardiogram. The family asks whether any treatment can clear the infection and reduce the chance of long-term heart disease.

Question: Which of the following is the most appropriate treatment?

Pick an answer to reveal the explanation.

CorrectIncorrect

The correct answer is D. Benznidazole (or nifurtimox).

Core Lens: High-Yield Takeaways

  • Benznidazole and nifurtimox are the two antitrypanosomal drugs for Chagas disease. — Both are recommended by PAHO/WHO; benznidazole is usually first choice, with nifurtimox as the alternative.
  • Treat early and treat children. — Antiparasitic therapy is most beneficial in acute infection, in congenital infection, and in children and young adults with chronic infection, where cure rates are highest and tolerability is best.
  • This child should be treated. — Every infected child should receive antiparasitic treatment; a 9-year-old with confirmed T. cruzi and no established cardiomyopathy is exactly the patient in whom treatment is clearly indicated.
  • Chronic cardiomyopathy is the late complication, not the trigger to treat. — Once advanced Chagas cardiomyopathy is established, antiparasitic treatment has not been shown to alter cardiac outcomes, so the window of greatest benefit is earlier.
Click here for Deep Dive

American Trypanosomiasis: A Lifelong Infection With a Narrowing Treatment Window

Chagas disease is caused by the protozoan Trypanosoma cruzi, transmitted chiefly by triatomine (“kissing”) bugs in Latin America, but also congenitally, through blood transfusion and organ donation, and occasionally orally. Acute infection is often mild or silent (sometimes with a chagoma or the periorbital Romaña sign), after which most people enter an indeterminate chronic phase that can last decades. Around a third eventually develop chronic Chagas cardiomyopathy — a dilated cardiomyopathy with conduction disease, arrhythmia, apical aneurysm and thromboembolism — and a minority develop digestive disease (megaoesophagus, megacolon). The therapeutic principle is that killing the parasite is most worthwhile before irreversible end-organ damage has occurred.

Why This Is the Right Move

PAHO/WHO guidance recommends antitrypanosomal treatment with benznidazole or nifurtimox for all acute and congenital infections and for chronic infection in children and adolescents, where parasitological cure is most achievable and the drugs are best tolerated. Treating children prevents progression and interrupts the natural history before cardiac or digestive damage develops, which is why “every infected child should be treated” is a firm recommendation. In adults with chronic indeterminate infection treatment is generally still offered (particularly in younger adults and women of child-bearing age, to prevent congenital transmission), but the evidence of benefit is weaker; in patients with established advanced cardiomyopathy, trial evidence shows antiparasitic therapy does not improve cardiac outcomes. For this asymptomatic 9-year-old, benznidazole (or nifurtimox) is clearly indicated.

Why the Other Options Don’t Fit

  • Option A: This reverses the evidence: treatment is most beneficial early and in children, and is of little cardiac benefit once advanced cardiomyopathy is established — waiting for cardiomyopathy is precisely the wrong strategy.
  • Option B: Liposomal amphotericin B treats leishmaniasis and systemic fungal infection, not T. cruzi.
  • Option C: Doxycycline has no role in Chagas disease; it is an antibacterial used for rickettsial and other bacterial infections.
  • Option E: Ivermectin is an antiparasitic for nematodes and ectoparasites and has no useful activity against T. cruzi.

“Red Flags” and Key Decision Points

  • Cardiac evaluation before and during follow-up. — New conduction abnormality (especially right bundle branch block with left anterior fascicular block), arrhythmia, heart failure or syncope signals evolving cardiomyopathy and needs cardiology assessment.
  • Congenital and reproductive risk. — Treating girls and women before pregnancy reduces congenital transmission; benznidazole and nifurtimox are not given during pregnancy itself.
  • Reactivation in immunosuppression. — HIV, transplantation or other immunosuppression can cause severe reactivation (including meningoencephalitis or acute myocarditis) and is an indication for treatment.
  • Drug toxicity and adherence. — Both drugs commonly cause adverse effects (dermatitis, gastrointestinal upset, peripheral neuropathy with benznidazole; anorexia and neuropsychiatric effects with nifurtimox), so courses are prolonged and need monitoring and support.

Relevance to Clinical Practice

With migration, Chagas disease is increasingly seen far from Latin America, and screening of at-risk people (including pregnant women and blood and organ donors) is a public-health priority because early-life treatment can prevent a lifetime of cardiac disease. In resource-limited endemic settings the emphasis is on vector control, screening of newborns of infected mothers, and timely benznidazole or nifurtimox for those who will benefit most — children and young adults — while ensuring cardiac follow-up for those with chronic infection. Recognising that the treatment window narrows with age, and that established cardiomyopathy is managed as heart failure rather than expecting antiparasitic cure, is the key clinical judgement.

Founder’s Tip

In Chagas disease the parasite is easiest to beat when the patient is youngest: treat acute, congenital and childhood infection without hesitation; once the heart is badly damaged, antiparasitic drugs no longer rescue it.

Core Summary: Confirmed T. cruzi infection in a child is treated with benznidazole (or nifurtimox); antitrypanosomal therapy is most beneficial in acute, congenital and childhood/young-adult infection, whereas it does not improve outcomes once advanced chronic cardiomyopathy is established.

DTM&H · The Returning Traveller & Travel MedicineQuestion 8 of 10 · single best answer

Yellow fever vaccination: contraindications

Scenario: A 46-year-old woman attends a yellow-fever clinic before a safari in Tanzania that requires a valid certificate. She has rheumatoid arthritis controlled on infliximab and low-dose methotrexate. She has no egg allergy, no thymus disorder, and has never reacted to a vaccine. She asks to be vaccinated today so she has a certificate for entry.

Question: What is the most appropriate course of action?

Pick an answer to reveal the explanation.

CorrectIncorrect

The correct answer is B. The live yellow fever vaccine should be withheld because she is significantly immunosuppressed, and a medical exemption (waiver) letter should be considered.

Core Lens: High-Yield Takeaways

  • Yellow fever vaccine is a live attenuated (17D) vaccine. — Significant immunosuppression is a contraindication because the attenuated virus can cause serious vaccine-associated disease in those who cannot contain it.
  • Biologics plus methotrexate count as significant immunosuppression. — A tumour necrosis factor inhibitor such as infliximab, especially combined with methotrexate, places her firmly in the contraindicated group under UK Green Book and NaTHNaC guidance.
  • A certificate is never a reason to give a contraindicated live vaccine. — Where vaccination is unsafe, an authorised yellow fever centre can issue a medical exemption letter, and the traveller should be counselled on rigorous bite avoidance and on entry-requirement risk.
  • Other true contraindications to know. — Infants under 6 months (absolute), thymus disorder, and anaphylaxis to a vaccine component (including egg) are the classic absolute contraindications; age 6–9 months and age 60+ are situations of caution requiring individual risk assessment.
Click here for Deep Dive

A Live Vaccine in an Immunosuppressed Host

The yellow fever 17D vaccine is highly effective, and a single dose is now considered to give lifelong protection for the purposes of the International Certificate of Vaccination or Prophylaxis (the International Health Regulations were amended in 2016 so that a valid certificate lasts the lifetime of the vaccinee). But it is a living, replicating virus. The rare but feared serious adverse events — yellow fever vaccine-associated viscerotropic disease and neurotropic disease — are concentrated in people whose immune systems cannot control viral replication: the significantly immunosuppressed, those with thymus disorders, and the very young or older. That is why the risk assessment, not the traveller’s certificate deadline, governs the decision.

Why This Is the Right Move

UK Green Book chapter 35 and NaTHNaC yellow fever guidance classify treatment with biologic agents such as TNF inhibitors, and immunosuppressive doses of conventional agents such as methotrexate, as significant immunosuppression that contraindicates this live vaccine. The correct action is therefore to withhold it and to consider issuing a medical exemption letter from an authorised yellow fever vaccination centre, which many destinations will accept in lieu of a certificate. She must also be counselled that an exemption removes certification but not risk: meticulous mosquito-bite avoidance is essential, and if the true risk of yellow fever exposure were high, deferring or modifying travel might be the safer option. Where appropriate, specialist and rheumatology input can help decide whether immunosuppression could ever be safely paused, but that is a specialist decision, not a clinic-day workaround.

Why the Other Options Don’t Fit

  • Option A: Vaccinating today ignores a clear contraindication and exposes her to potentially fatal viscerotropic or neurotropic disease — the certificate requirement does not override safety.
  • Option C: Dose reduction is not a recognised way to make a live vaccine safe in immunosuppression; a fractional dose is only ever considered in supply-shortage outbreak settings, not to bypass a contraindication.
  • Option D: A two-week deferral changes nothing, because her immunosuppression is ongoing; only a properly planned, specialist-led washout (if ever appropriate) would alter the contraindication.
  • Option E: There is no antiviral prophylaxis that makes the live yellow fever vaccine safe in an immunosuppressed person; this is not a recognised strategy.

“Red Flags” and Key Decision Points

  • Significant immunosuppression: biologics, high-dose or prolonged corticosteroids, immunosuppressive chemotherapy, and HIV with low CD4 counts all contraindicate or require specialist assessment for live vaccines.
  • Infant age: the vaccine is absolutely contraindicated under 6 months and used only with caution and individual assessment between 6 and 9 months.
  • Thymus disorder or prior thymectomy for thymoma: an absolute contraindication owing to the risk of viscerotropic disease.
  • Anaphylaxis to egg or another vaccine component, and age 60 and over: true allergy contraindicates, while older age is a precaution prompting careful first-dose risk assessment.

Relevance to Clinical Practice

Yellow fever vaccination in the UK is restricted to registered centres precisely because these risk assessments matter. The practical workflow is to screen every candidate for immunosuppression, age extremes, thymus disorders and component allergy before drawing up the vaccine, and to know that a medical exemption letter is the safe route when vaccination is contraindicated. In resource-limited or outbreak contexts the benefit-risk balance can shift, but the default for an immunosuppressed traveller attending an elective safari is to withhold and protect by other means.

Founder’s Tip

A required certificate is a reason to write an exemption letter, never a reason to put a live virus into an immunosuppressed traveller.

Core Summary: The live attenuated yellow fever vaccine is contraindicated in significant immunosuppression (here, infliximab plus methotrexate); withhold it, consider a medical exemption letter, and rely on rigorous bite avoidance — while remembering a single dose now confers lifelong certificate validity for those who can safely receive it.

DTM&H · Tuberculosis & LeprosyQuestion 9 of 10 · single best answer

TB & Leprosy: paucibacillary leprosy classification and WHO MDT

Scenario: A 26-year-old man in a leprosy-endemic region presents with two well-defined, pale, anaesthetic skin patches on his forearm and back, present for several months. Slit-skin smears performed at the clinic are negative for acid-fast bacilli. No thickened peripheral nerve is detected and there are no other lesions. A diagnosis of leprosy is made.

Question: How should his disease be classified and treated according to WHO guidance?

Pick an answer to reveal the explanation.

CorrectIncorrect

The correct answer is E. Paucibacillary leprosy; treat with rifampicin, dapsone and clofazimine for 6 months.

Core Lens: High-Yield Takeaways

  • Five or fewer skin lesions with a negative smear is paucibacillary leprosy. — The WHO operational classification uses lesion count: up to five skin lesions defines paucibacillary (PB) disease, more than five defines multibacillary (MB); nerve involvement or a positive smear classifies as MB regardless of lesion number.
  • WHO now uses the same three drugs for both forms. — Since 2018, WHO recommends rifampicin, dapsone and clofazimine for all patients, differing only in duration.
  • Duration is the key distinction: PB for 6 months, MB for 12 months. — This man, with two anaesthetic patches and a negative smear, has PB leprosy and receives the three-drug regimen for six months.
  • Monotherapy is never acceptable. — Treating leprosy with a single drug breeds resistance; multidrug therapy is mandatory, which is why dapsone alone is wrong.
Click here for Deep Dive

Classifying Leprosy for Treatment

Leprosy exists on an immunological spectrum from tuberculoid (few lesions, strong cell-mediated immunity, scanty bacilli) to lepromatous (many lesions, weak cell-mediated immunity, abundant bacilli). For programmatic treatment in the field, WHO simplified this into an operational classification based on what a clinician can readily assess: the number of skin lesions and, where available, the slit-skin smear. Up to five skin patches with a negative smear is paucibacillary; six or more lesions, nerve involvement, or any positive smear, is multibacillary. This pragmatic split lets health workers without laboratory backup choose the right regimen. The patient here has two well-defined anaesthetic patches and a negative smear – clearly paucibacillary.

Why This Is the Right Move

The WHO 2018 guidelines for the diagnosis, treatment and prevention of leprosy harmonised the regimen so that all patients receive the same three drugs – rifampicin, dapsone and clofazimine – with the duration set by classification: six months for paucibacillary disease and twelve months for multibacillary disease. The historic two-drug PB regimen (rifampicin plus dapsone) was replaced by the three-drug combination to reduce relapse and simplify supply. So the correct management is rifampicin, dapsone and clofazimine for six months. The drugs are provided in standard WHO blister packs combining a monthly supervised dose (including rifampicin) with daily self-administered doses, which aids adherence in resource-limited programmes.

Why the Other Options Don’t Fit

  • Option A: With only two lesions and a negative smear this is paucibacillary, not multibacillary; twelve months of treatment is the MB duration and would over-treat him.
  • Option B: Dapsone monotherapy is obsolete and dangerous – single-drug treatment generates resistance, and current WHO PB treatment is three drugs, not one.
  • Option C: This misclassifies the disease as MB and uses the outdated two-drug combination; current guidance uses three drugs and reserves the 12-month duration for MB disease.
  • Option D: The single-dose rifampicin-ofloxacin-minocycline (ROM) regimen is not the standard WHO PB course; standard treatment is six months of rifampicin, dapsone and clofazimine.

“Red Flags” and Key Decision Points

  • More than five lesions, a positive smear, or any nerve thickening: reclassify towards multibacillary and treat for the longer 12-month course.
  • New or worsening nerve function or painful skin lesions during treatment: consider a leprosy reaction, which needs separate management and may require corticosteroids – and does not mean treatment failure.
  • Glucose-6-phosphate dehydrogenase deficiency: dapsone can precipitate haemolysis; consider this in endemic regions and monitor accordingly.
  • Pregnancy: standard multidrug therapy is considered safe and should be continued; leprosy may flare in pregnancy and the puerperium.

Relevance to Clinical Practice

The genius of the WHO operational classification is that it requires no sophisticated laboratory – a clinician can count lesions and, ideally, perform a slit-skin smear, then pick the regimen. For clinicians in tropical and global-health settings the practical points are to examine the whole skin in good light, test lesions for sensory loss, palpate peripheral nerves, document the lesion count that determines classification, and counsel the patient that completing the full multidrug course – six months for PB – cures the infection and prevents resistance even though existing nerve damage will not reverse. Contact tracing and single-dose rifampicin post-exposure prophylaxis for contacts are increasingly part of programmatic care.

Founder’s Tip

Count the patches: up to five with a negative smear is paucibacillary – rifampicin, dapsone and clofazimine for six months. More than five, or a positive smear, makes it multibacillary and twelve months.

Core Summary: Up to five anaesthetic skin lesions with a negative slit-skin smear defines paucibacillary leprosy; the current WHO regimen is rifampicin, dapsone and clofazimine for six months (multibacillary disease uses the same three drugs for twelve months), and monotherapy is never acceptable.

DTM&H · Zoonoses, Envenomation & Other Bacterial InfectionsQuestion 10 of 10 · single best answer

Rabies: post-exposure prophylaxis

Scenario: A 26-year-old traveller, who has never received any rabies vaccine, is bitten on the forearm by a stray dog while trekking in rural Nepal. The bite has broken the skin and is bleeding. She presents to a clinic a few hours later. Rabies is endemic in the area and the dog cannot be traced or observed.

Question: According to WHO guidance, what is the most appropriate management of this category III exposure?

Pick an answer to reveal the explanation.

CorrectIncorrect

The correct answer is E. Immediate thorough wound washing plus a course of rabies vaccine plus rabies immunoglobulin infiltrated around the wound.

Core Lens: High-Yield Takeaways

  • Category III exposure in an unvaccinated person needs all three components. — Wound washing, rabies vaccine and rabies immunoglobulin (RIG) together make up complete post-exposure prophylaxis for a transdermal bite in an endemic area.
  • Wound washing is the first and cheapest life-saver. — Immediate, thorough flushing and washing of the wound for at least 15 minutes with soap and water (or a virucidal agent such as povidone-iodine) substantially reduces the risk of rabies.
  • RIG is infiltrated into and around the wound, not the buttock. — The maximum anatomically feasible amount of RIG is infiltrated in and around all wounds to neutralise virus locally before the vaccine-induced antibody response develops; it is given once, at or near the start of prophylaxis.
  • Rabies is essentially always fatal once symptomatic. — Prophylaxis is a medical emergency: there is no effective treatment once clinical rabies appears, so the time to act is now, not when symptoms develop.
Click here for Deep Dive

The Disease You Must Prevent Because You Cannot Cure It

Rabies is a virtually uniformly fatal viral encephalitis transmitted in saliva, most often by dog bites in endemic regions, which account for the overwhelming majority of the tens of thousands of human deaths each year. The virus travels along peripheral nerves to the central nervous system; once it reaches the brain and symptoms begin (hydrophobia, aerophobia, agitation or a paralytic form), death is almost inevitable. Everything therefore hinges on prompt, correct post-exposure prophylaxis during the incubation period, before the virus reaches the nervous system. WHO classifies exposures into three categories: category I (touching/feeding, intact skin) needs no prophylaxis; category II (minor scratches or nibbling on uncovered skin without bleeding) needs wound care and vaccine; category III (transdermal bites or scratches, licks on broken skin or mucosa, or bat contact) needs wound care, vaccine and RIG.

Why This Is the Right Move

This is a textbook category III exposure: a transdermal dog bite that has broken the skin, in a rabies-endemic area, in a person with no previous rabies vaccination. WHO guidance specifies all three elements. First, immediate and thorough wound washing for at least 15 minutes. Second, a complete course of rabies vaccine by a WHO-recommended schedule (intramuscular or intradermal). Third, because she is immunologically naïve, rabies immunoglobulin infiltrated into and around the wound to provide immediate passive protection while the vaccine response matures over the next week or so; any wound requiring suturing should be closed loosely and only after RIG infiltration. RIG is given once and ideally at the start of prophylaxis (and no later than seven days after the first vaccine dose).

Why the Other Options Don’t Fit

  • Option A: Vaccine alone omits both the wound washing that immediately lowers risk and, for a category III exposure in an unvaccinated person, the RIG needed for early passive protection.
  • Option B: Antibiotics and tetanus cover are reasonable adjuncts for any bite wound, but they do nothing against rabies; relying on observing an untraceable stray dog while giving no rabies prophylaxis could be fatal.
  • Option C: RIG should be infiltrated into and around the wound, not injected into the gluteal muscle, and it must be combined with vaccine and wound care — immunoglobulin alone is inadequate.
  • Option D: Rabies vaccine is given as a full multi-dose course starting immediately; a single dose deferred until symptoms appear would be useless, because prophylaxis cannot work once clinical rabies has developed.

“Red Flags” and Key Decision Points

  • Bat exposure. — Any direct contact with a bat is treated as a category III exposure even when no bite is seen, because bat bites can be tiny and unnoticed.
  • Head, neck, hand and multiple/deep wounds. — Heavily innervated or severe sites carry shorter incubation and higher risk; ensure RIG infiltration and prompt vaccine without delay.
  • Previously vaccinated patients. — Those with documented prior rabies vaccination need only two booster vaccine doses and do not require RIG, which is reserved for the immunologically naïve.
  • Immunocompromise and delayed presentation. — Prophylaxis is still indicated however late the patient presents (until symptoms appear); immunosuppressed patients may need careful, complete regimens and serological checks.

Relevance to Clinical Practice

For travellers, the practical messages are pre-travel risk assessment (pre-exposure vaccination for higher-risk trips simplifies and shortens any later post-exposure course and removes the need for RIG), and immediate first aid — wash the wound at once — followed by urgent presentation for vaccine and RIG. In many endemic, resource-limited settings RIG is scarce or unavailable; WHO is clear that where RIG cannot be obtained, prompt wound washing plus immediate and complete vaccination is still highly effective and must not be delayed while searching for immunoglobulin. Knowing the exposure categories, and that category III in an unvaccinated person mandates all three components, is core travel-medicine practice.

Founder’s Tip

For a bleeding bite in an unvaccinated traveller: wash for 15 minutes, vaccinate, and put the immunoglobulin into the wound — never into the buttock, and never wait for symptoms.

Core Summary: A category III rabies exposure in an unvaccinated person requires immediate thorough wound washing, a full course of rabies vaccine, and rabies immunoglobulin infiltrated into and around the wound; where RIG is unavailable, prompt wound washing plus complete vaccination remains highly effective.

corerevision.com/dtmh-question-bank
DTM&H Question Bank850 questions · 12 modules · your progress saves as you go
  • Arboviruses & Viral Haemorrhagic Fevers75%
  • Enteric & Diarrhoeal Infections60%
  • Helminth Infections40%
  • HIV & Tropical Co-infection20%
  • Malaria—
  • Nutrition, Maternal & Child Health & Tropical NCDs—
  • Parasitology & Entomology—
  • Protozoal Infections—
  • Public Health, Prevention & Tropical Hygiene—
  • The Returning Traveller & Travel Medicine—
  • + 2 more modules
Drill (untimed)Timed mockWeak spots

What it looks like inside: every module tracks your accuracy, so the bank tells you where to revise next. Timed mocks reproduce the written paper; untimed drills give the explanation after every question.

The DTM&H ecosystem

Your full DTM&H toolkit

Beyond the question bank — map the syllabus, sharpen high-yield reasoning, check your readiness, and plan your run-up.

CurriculumCore CurriculumRAG-rate every topic; what to focus on, the traps, the exam triggers.LensCore LensEach topic through the exam’s eyes: safety cue, guideline point, exam trap.ToolsCore ToolsInteractive reason-then-reveal decoders for the high-yield topics.CompassCore CompassRate your readiness and see exactly where to focus next.CalendarCore CalendarA calm, week-by-week plan counting back to your exam date.WisdomCore WisdomShort, practical mentor notes for the exam.Core 10The Core 10Ten focused minutes of questions a day, weighted to your plan and your shakiest topics.Paper 3The SSQ TrainerTwelve short structured questions in the shape of Paper 3, with model marking points.

Quick answers about the DTM&H

Checked against the Society of Apothecaries' own pages on 16 October 2026.

When is the next DTM&H exam?

Tuesday 25 May 2027. The Society of Apothecaries says applications will open in due course. The closing date and the fee are still to be confirmed.

Who runs the DTM&H now?

The Worshipful Society of Apothecaries. The Royal College of Physicians used to administer it.

What does the DTM&H exam involve?

Four papers, which the Society lists as online, to be confirmed. About 60% covers clinical infectious diseases and tropical medicine, 15% non-communicable disease in the tropics and 25% preventive medicine and international public health.

Do I need a course for the DTM&H?

Yes. You must complete an approved course first. The Society expects about 250 hours of teaching, either three months full time or six months part time.

Who can sit the DTM&H?

Doctors who have held their medical qualification for at least a year and have completed an approved course. You need GMC registration or a medical degree from an internationally recognised institution.

How much does the DTM&H cost?

The exam fee was £570 in 2026. The 2027 fee is still to be confirmed. Course fees are separate.

What do I get with Core Revision's DTM&H access?

850 best-of-five questions with teaching explanations, a 100-specimen image bank, the twelve-chapter revision guide and the SSQ Trainer. Access is £49.99 for 12 months, paid once. You can try ten questions free first.

Our free guides to the DTM&H

Dates, fees, format and revision plans, checked against the college’s own pages. Newest first. Still choosing a diploma? Compare all eight side by side.